Nestlé`s Diversification through Palforzia: The Setback and Lessons

Nestlé`s Diversification through Palforzia: The Setback and Lessons
Case Code: BSTR663
Case Length: 13 Pages
Period: -
Pub Date: 2023
Teaching Note: Available
 Price: Rs.400
Organization : Nestlé S.A.
Industry : Food & Beverage
Countries : United States
Themes: M&A, Diversification Strategy, Product Strategy & Design,New Product Development
Nestlé`s Diversification through Palforzia: The Setback and Lessons
Abstract Case Intro 1 Case Intro 2 Excerpts

Introduction

As of July 2023, Swiss multinational food and beverage conglomerate Nestlé S.A. (Nestlé) was stated to be in talks with biopharmaceutical company Stallergenes Greer International AG (Stallergenes) on the possible divestiture of its peanut allergy medicine, Palforzia. The potential sale was stated to be part of Nestlé’s strategic efforts to focus on core areas and ensure that its product offerings were in line with its long-term growth strategy..

Buy this case study (Please select any one of the payment options)

Price: Rs.400
 Price: Rs.400
 PayPal (9 USD)

Custom Search